Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1993 Jun;67(6):1248–1253. doi: 10.1038/bjc.1993.233

Targeting of saporin to CD25-positive normal and neoplastic lymphocytes by an anti-saporin/anti-CD25 bispecific monoclonal antibody: in vitro evaluation.

P L Tazzari 1, S Zhang 1, Q Chen 1, S Sforzini 1, A Bolognesi 1, F Stirpe 1, H Xie 1, A Moretta 1, S Ferrini 1
PMCID: PMC1968507  PMID: 8512810

Abstract

This study has been designed to verify the specific toxicity of saporin, a type 1 ribosome-inactivating protein (RIP), with the same activity as ricin A chain, targeted by a bispecific monoclonal antibody (bimAb) recognising both the CD25 antigen and the RIP. The CD25 antigen is expressed by lymphoid populations upon activation and by leukaemias and lymphomas with an activated membrane phenotype (Hodgkin's lymphoma, anaplastic large cell lymphoma, adult T cell leukaemia). The bimAb-saporin mixture was tested on CD25+ targets at different bimAb and saporin concentrations. Saporin, in the presence of a bimAb concentration of 10(-9) M, inhibited protein synthesis by CD25+ neoplastic lymphocytes (L540 and MT2 cell lines) with IC50S (concentrations giving 50% of inhibition) ranging from 8 x 10(-12) M to 3 x 10(-11) M. The saporin-bimAb mixture was also effective in blocking the phytohaemagglutinin-driven proliferation of normal lymphocytes, whereas it displayed the same level of toxicity exerted by saporin alone on an irrelevant CD25-negative cell line (EBV-infected B lymphoblastoid cell line). From these results it is possible to envisage a clinical use of this bimAb as a cytotoxic agent for CD25+ leukaemias and lymphomas, as well as an immunosuppressive agent for severe immune disorders such as graft-vs-host disease (GVHD) and transplanted organ rejection.

Full text

PDF
1248

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bonardi M. A., Bell A., French R. R., Gromo G., Hamblin T., Modena D., Tutt A. L., Glennie M. J. Initial experience in treating human lymphoma with a combination of bispecific antibody and saporin. Int J Cancer Suppl. 1992;7:73–77. [PubMed] [Google Scholar]
  2. Clark M. R., Waldmann H. T-cell killing of target cells induced by hybrid antibodies: comparison of two bispecific monoclonal antibodies. J Natl Cancer Inst. 1987 Dec;79(6):1393–1401. [PubMed] [Google Scholar]
  3. Dukovich M., Wano Y., Le thi Bich Thuy, Katz P., Cullen B. R., Kehrl J. H., Greene W. C. A second human interleukin-2 binding protein that may be a component of high-affinity interleukin-2 receptors. Nature. 1987 Jun 11;327(6122):518–522. doi: 10.1038/327518a0. [DOI] [PubMed] [Google Scholar]
  4. Engert A., Burrows F., Jung W., Tazzari P. L., Stein H., Pfreundschuh M., Diehl V., Thorpe P. Evaluation of ricin A chain-containing immunotoxins directed against the CD30 antigen as potential reagents for the treatment of Hodgkin's disease. Cancer Res. 1990 Jan 1;50(1):84–88. [PubMed] [Google Scholar]
  5. Ferrini S., Prigione I., Mammoliti S., Colnaghi M. I., Ménard S., Moretta A., Moretta L. Re-targeting of human lymphocytes expressing the T-cell receptor gamma/delta to ovarian carcinoma cells by the use of bispecific monoclonal antibodies. Int J Cancer. 1989 Aug 15;44(2):245–250. doi: 10.1002/ijc.2910440210. [DOI] [PubMed] [Google Scholar]
  6. Ferrini S., Prigione I., Miotti S., Ciccone E., Cantoni C., Chen Q., Colnaghi M. I., Moretta L. Bispecific monoclonal antibodies directed to CD16 and to a tumor-associated antigen induce target-cell lysis by resting NK cells and by a subset of NK clones. Int J Cancer. 1991 May 10;48(2):227–233. doi: 10.1002/ijc.2910480213. [DOI] [PubMed] [Google Scholar]
  7. Glennie M. J., Brennand D. M., Bryden F., McBride H. M., Stirpe F., Worth A. T., Stevenson G. T. Bispecific F(ab' gamma)2 antibody for the delivery of saporin in the treatment of lymphoma. J Immunol. 1988 Nov 15;141(10):3662–3670. [PubMed] [Google Scholar]
  8. Hervé P., Wijdenes J., Bergerat J. P., Bordigoni P., Milpied N., Cahn J. Y., Clément C., Béliard R., Morel-Fourrier B., Racadot E. Treatment of corticosteroid resistant acute graft-versus-host disease by in vivo administration of anti-interleukin-2 receptor monoclonal antibody (B-B10) Blood. 1990 Feb 15;75(4):1017–1023. [PubMed] [Google Scholar]
  9. Laky M., Mota G., Moraru I., Ghetie V. Binding and cytotoxic effect of ricin toxin on multivalent hybrid antibody-coated target cells. Immunol Lett. 1987 Jan;14(2):127–132. doi: 10.1016/0165-2478(87)90091-5. [DOI] [PubMed] [Google Scholar]
  10. Lanzavecchia A., Scheidegger D. The use of hybrid hybridomas to target human cytotoxic T lymphocytes. Eur J Immunol. 1987 Jan;17(1):105–111. doi: 10.1002/eji.1830170118. [DOI] [PubMed] [Google Scholar]
  11. Marcucci F., Lappi D. A., Ghislieri M., Martineau D., Formosa A., Siena S., Bregni M., Soria M., Gianni A. M. In vivo effects in mice of an anti-T cell immunotoxin. J Immunol. 1989 Apr 15;142(8):2955–2960. [PubMed] [Google Scholar]
  12. Miyoshi I., Kubonishi I., Yoshimoto S., Akagi T., Ohtsuki Y., Shiraishi Y., Nagata K., Hinuma Y. Type C virus particles in a cord T-cell line derived by co-cultivating normal human cord leukocytes and human leukaemic T cells. Nature. 1981 Dec 24;294(5843):770–771. doi: 10.1038/294770a0. [DOI] [PubMed] [Google Scholar]
  13. Robb R. J., Rusk C. M., Yodoi J., Greene W. C. Interleukin 2 binding molecule distinct from the Tac protein: analysis of its role in formation of high-affinity receptors. Proc Natl Acad Sci U S A. 1987 Apr;84(7):2002–2006. doi: 10.1073/pnas.84.7.2002. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Siena S., Lappi D. A., Bregni M., Formosa A., Villa S., Soria M., Bonadonna G., Gianni A. M. Synthesis and characterization of an antihuman T-lymphocyte saporin immunotoxin (OKT1-SAP) with in vivo stability into nonhuman primates. Blood. 1988 Aug;72(2):756–765. [PubMed] [Google Scholar]
  15. Staerz U. D., Bevan M. J. Hybrid hybridoma producing a bispecific monoclonal antibody that can focus effector T-cell activity. Proc Natl Acad Sci U S A. 1986 Mar;83(5):1453–1457. doi: 10.1073/pnas.83.5.1453. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Stirpe F., Gasperi-Campani A., Barbieri L., Falasca A., Abbondanza A., Stevens W. A. Ribosome-inactivating proteins from the seeds of Saponaria officinalis L. (soapwort), of Agrostemma githago L. (corn cockle) and of Asparagus officinalis L. (asparagus), and from the latex of Hura crepitans L. (sandbox tree). Biochem J. 1983 Dec 15;216(3):617–625. doi: 10.1042/bj2160617. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Suresh M. R., Cuello A. C., Milstein C. Bispecific monoclonal antibodies from hybrid hybridomas. Methods Enzymol. 1986;121:210–228. doi: 10.1016/0076-6879(86)21019-8. [DOI] [PubMed] [Google Scholar]
  18. Tazzari P. L., Barbieri L., Gobbi M., Dinota A., Rizzi S., Bontadini A., Pession A., Tura S., Stirpe F. An immunotoxin containing a rat IgM monoclonal antibody (Campath 1) and saporin 6: effect on T lymphocytes and hemopoietic cells. Cancer Immunol Immunother. 1988;26(3):231–236. doi: 10.1007/BF00199934. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Tazzari P. L., Bolognesi A., De Totero D., Pileri S., Conte R., Wijdenes J., Hervé P., Soria M., Stirpe F., Gobbi M. B-B10 (anti-CD25)-saporin immunotoxin--a possible tool in graft-versus-host disease treatment. Transplantation. 1992 Aug;54(2):351–356. doi: 10.1097/00007890-199208000-00029. [DOI] [PubMed] [Google Scholar]
  20. Tazzari P. L., Bolognesi A., de Totero D., Falini B., Lemoli R. M., Soria M. R., Pileri S., Gobbi M., Stein H., Flenghi L. Ber-H2 (anti-CD30)-saporin immunotoxin: a new tool for the treatment of Hodgkin's disease and CD30+ lymphoma: in vitro evaluation. Br J Haematol. 1992 Jun;81(2):203–211. doi: 10.1111/j.1365-2141.1992.tb08208.x. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES